High-density lipoproteins rescue diabetes-impaired angiogenesis via scavenger receptor class B type I by Tan, Joanne T.M. et al.
  
 
 
 
 
Tan, J. T.M. et al. (2016) High-density lipoproteins rescue diabetes-impaired 
angiogenesis via scavenger receptor class B type I. Diabetes, 65(10), pp. 3091-3103. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/147143/ 
     
 
 
 
 
 
 
Deposited on: 25 September 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
High Density Lipoproteins Rescue Diabetes-Impaired Angiogenesis via Scavenger 
Receptor Class B Type I 
 
HDL rescues diabetes-impaired angiogenesis 
 
Joanne T.M. Tan1,2§^, Hamish C.G. Prosser1,2§, Louise L. Dunn1,2, Laura Z. Vanags1,2, 
Anisyah Ridiandries1,2, Tania Tsatralis1, Laura Leece1,2, Zoë E. Clayton1,2, Sui Ching G. 
Yuen1,2, Stacy Robertson1,2, Yuen Ting Lam1,2, David S. Celermajer1,2,3, Martin K.C. Ng1,2,3†, 
Christina A. Bursill1,2†^ 
§,† Equal author contributions to publication. 
 
1. The Heart Research Institute, Sydney, Australia 
2. Sydney Medical School, University of Sydney, Sydney, Australia 
3. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia 
 
^Joint Corresponding Authors: 
J.T.M. Tan, Immunobiology Group, The Heart Research Institute,  
7 Eliza St, Newtown, NSW 2042, Australia. 
Telephone No: 61-2-8208 8900    Fax No: 61-2-9565 5584 
Email: joanne.tan@hri.org.au 
 
Total word count: 3997 words 
Number of tables and figures: 8 figures 
  
2 
 
Abstract 
 
Disordered neovascularization and impaired wound healing are important contributors to 
diabetic vascular complications. We recently showed that high-density lipoproteins (HDL) 
enhance ischemia-mediated neovascularization and mounting evidence suggests HDL have 
anti-diabetic properties. We therefore hypothesized that HDL rescue diabetes-impaired 
neovascularization. Streptozotocin-induced diabetic mice had reduced blood flow recovery 
and neovessel formation in a hindlimb ischemia model compared to non-diabetic mice. 
Reconstituted HDL (rHDL) infusions in diabetic mice restored blood flow recovery and 
capillary density to non-diabetic levels. Topical rHDL application rescued diabetes-impaired 
wound closure, wound angiogenesis and capillary density. In vitro, rHDL increased key 
mediators involved in HIF-1 stabilization including the PI3K/Akt pathway, Siah1 and 
Siah2, and suppressed the prolyl hydroxylases PHD2 and PHD3. rHDL rescued high glucose-
induced impairment of tubulogenesis and VEGFA protein production, a finding associated 
with enhanced phosphorylation of pro-angiogenic mediators VEGF receptor 2 (VEGFR2) 
and eNOS. Siah1/2 siRNA knockdown confirmed the importance of HIF-1 stability in 
mediating rHDL action. Lentiviral shRNA knockdown of scavenger receptor-BI (SR-BI) in 
vitro and SR-BI-/- diabetic mice in vivo, attenuated rHDL rescue of diabetes-impaired 
angiogenesis, indicating a key role for SR-BI. These findings provide a greater understanding 
of the vascular biological effects of HDL, with potential therapeutic implications for diabetic 
vascular complications. 
 
  
3 
 
Introduction 
The vascular complications of diabetes mellitus are characterized by disordered angiogenesis 
and impairment of ischemia-induced neovascularization. Sufferers of diabetes have reduced 
coronary collateral formation following vascular occlusion (1), impaired wound healing, and 
increased rates of amputation (2). Despite advances in the treatment of athero-occlusive 
disease and the demonstration that intensive blood glucose control attenuates some vascular 
complications, many diabetic patients with vasculopathy remain refractory to current 
treatment approaches.  
 
Diabetes-impaired ischemia-induced neovascularization is associated with decreased hypoxia 
inducible factor-1α (HIF-1α) stability (3; 4), reduced vascular endothelial growth factor 
(specifically VEGFA) production and signaling via VEGF receptor 2 (VEGFR2) (5), and 
inhibition of endothelial nitric oxide synthase (eNOS) activity (6). However, the key triggers 
for these events are incompletely understood, as are potential therapies to minimize these 
abnormalities. 
 
To date, pre-clinical studies have consistently demonstrated that high-density lipoproteins 
(HDL) and its main protein constituent apolipoprotein (apo)A-I, exert anti-atherogenic effects 
(7). Despite this, randomized trials of HDL-raising therapies have not demonstrated clinical 
benefit. However, long-term mortality follow-up of the Helsinki Heart study found that the 
incidence of coronary heart disease was significantly reduced when HDL levels were raised 
by only 5-10% (8), indicating that the biology of HDL is yet to be fully elucidated and 
perhaps aggressive attempts to raise HDL have other effects at the cellular and molecular 
level. Increasing evidence demonstrates that HDL exerts endothelial protective and anti-
diabetic effects. Infusions of rHDL reduce plasma glucose levels, restore impaired 
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endothelial function (9) and promote endothelial progenitor cell mobilization (10) in Type 2 
diabetic patients. HDL interacts with the cholesterol transporters ABCA1 and ABCG1, and 
scavenger receptor class B type I (SR-BI). While ABCA1 and ABCG1 are predominantly 
involved in HDL-mediated cholesterol efflux, SR-BI is known to mediate the vasculo-
protective effects of HDL including increasing re-endothelialization and endothelial cell 
migration (11; 12). Despite a significant amount of work, the vascular biological effects of 
HDL remain incompletely understood and further efforts to translate HDL into a potential 
therapeutic agent require a fuller understanding of its properties. 
 
We therefore sought to investigate the effect of rHDL on diabetes-impaired angiogenesis in 
two murine models of diabetic vascular complications; and to elucidate the mechanisms of 
action. We report that rHDL rescues diabetes-related impairment of ischemia-driven 
angiogenesis and wound healing. This occurs via the receptor SR-BI and by HIF-1 
stabilization, enhanced VEGFA/VEGFR2 production and signaling, and increased eNOS 
activity. These findings may have implications for therapeutic modulation of diabetic 
vascular complications. 
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Research Design and Methods 
Preparation of discoidal reconstituted HDL 
Apolipoprotein A-I (apoA-I) was isolated from plasma obtained from a pool of multiple 
healthy donors (>5) by ultracentrifugation and anion-exchange chromatography, as described 
previously (13). Discoidal reconstituted HDL (rHDL) was prepared by complexing apoA-I 
with 1-palmitoyl-2-linoleoyl-phosphatidylcholine.  
 
Animal studies 
All experimental procedures were conducted with approval from the Sydney Local Health 
District Animal Welfare Committee. Male 8-week-old C57Bl/6J, SR-BI-/- and wildtype (WT) 
littermates were rendered diabetic two weeks prior to surgery by a bolus i.p. injection of 
streptozotocin (165 µg/g).  
 
Murine hindlimb ischemia model 
The hindlimb ischemia model was conducted as described previously (14). The left femoral 
artery and vein were ligated and excised from the hindlimb of mice (n=8–12/group). A sham 
procedure was performed on the opposite hindlimb. Mice received i.v. injections of PBS 
(vehicle control) or rHDL (200 g/mouse) via the tail vein every second day following 
surgery. Hindlimb blood reperfusion was determined by laser Doppler perfusion imaging 
prior to and immediately following surgery, then at Days 2–3, 7, and 10 post-surgery.  
 
Murine wound healing model 
The wound healing model was conducted as previously described (15). Two full-thickness 
excisions were created on the dorsum and a silicone splint secured around the wound. For 
each mouse, one wound received rHDL (50 µg/wound/day) and the other PBS topically 
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applied directly on the wound. A transparent occlusive dressing (OpsiteTM) was applied. 
Digital images and wound area were measured daily. Wound blood perfusion was determined 
using laser Doppler.  
 
Plasma lipid and glucose concentrations 
Total, HDL and LDL cholesterol concentrations on mouse plasma were determined 
enzymatically (Roche Diagnostics). HDL cholesterol concentrations were determined 
following polyethylene glycol precipitation of apolipoprotein B containing lipoproteins. 
Glucose concentrations were measured using a glucometer (AccuCheck Performa). 
 
Immunocytochemistry 
Fresh frozen 5 µm sections of gastrocnemius muscle from ischemic and non-ischemic 
hindlimbs were stained to detect the number of new capillaries (CD31+, Dako) per myocyte 
(laminin, abcam). 5 µm sections were taken from the mid-point of paraffin-embedded wound 
tissues and assessed for CD31+ neovessels (abcam).  
 
Cell culture 
Human coronary artery endothelial cells (HCAECs, Cell Applications) were cultured in 
MesoEndo media and used at passages 4–5. Cells were seeded at 8x104 cells/well and 
cultured for 8 hours, then treated for 18 hours with rHDL (20 µM, final apoA-I 
concentration) or PBS. Cells were replaced with fresh DMEM media in glucose conditions 
for 48 hours. For high glucose conditions, media was supplemented with D-glucose to a final 
concentration of 25 mM. For the measurement of phosphorylated proteins, cells were 
stimulated with 10 ng/mL rhVEGF protein (R&D Systems). Each experiment was performed 
three times independently and in triplicate. 
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Siah1/2 knockdown in HCAECs 
HCAECs were transfected for 6 hours with 60 nM siRNA for Siah1, Siah2 or control 
scrambled (Santa Cruz Biotechnology, Inc.) then treated with rHDL (20 µM) or PBS for 18 
hours and exposed to high glucose (25 mM, 48 hours). 
 
SR-BI knockdown in HCAECs  
Lentiviruses containing either shRNA for SR-BI (shSR-BI) or the empty vector (shControl) 
were generated in 293T17 cells as described previously (16; 17). Viral titres were quantified 
using Lenti-XTM qRT-PCR Titration Kit (Clontech). 
HCAECs were seeded and grown overnight to 50% confluency, then exposed for 24 hours to 
1x107 lentiviral particles/mL containing either shSR-BI or shControl. Transduced cells were 
seeded at 8x104 cells/well. Cells were treated with rHDL (20 µM) or PBS for 18 hours then 
exposed to high glucose (25 mM, 48 hours).  
 
RNA expression 
Quantitative real-time PCR was performed for (1) murine Glut1 (F:5’-
TCAACACGGCCTTCACTG-3’; R:5’-CACGATGCTCAGATAGGACATC-3’), Ppargc1a 
(F:5’-TGGAGTGACATAGAGTGTGCTG-3’; R:5’-TGTTCGCAGGCTCATTGTTG-3’), 
Hif-2α (F:5’-AGGTCTGCAAAGGACTTCGG-3’; R:5’-CAAGTGTGAACTGCTGGTGC-
3’), Phd1, (F:5'-TAAGGTGCATGGCGGCCTGC-3'; R:5'-TGGCTGCTGCCCGTTCCTTG-
3'), Pdk4 (F:5’-CACGTACTCCACTGCTCCAA-3’; R:5’-AGCGTCTGTCCCATAACCTG-
3’), Scarb1 (F:5’-CTGAGCACGTTCTACACGCA-3’; R:5’-
GGCCTGAATGGCCTCCTTAT-3’), Siah1a (F:5’-GACTGCTACAGCATTACCCACT-3’; 
R:5’-GTTGGATGCAGTTGTGCCG-3’), Siah2 (F:5’-CTAACGCCCAGCATCAGGAA-3’; 
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R:5’-GAACAGCCCGTGGTAGCATA-3’), Hif-1α (F:5’-
TCCCTTGCTCTTTGTGGTTGGGT-3’; R:5’-AACGTAAGCGCTGACCCAGG-3’), Vegfa 
(F:5’-GGCTGCTGTAACGATGAAG-3’; R:5’-CTCTCTATGTGCTGGCTTTG-3’), Vegfr2 
(F:5’-GCCCAGACTGTGTCCCGCAG-3’; R:5’-AGCGCAAGACCGGGGAGAGC-3’) and 
36B4 (F:5’-CAACGGCAGCATTTATAACCC-3’; R:5’-CCCATTGATGATGGAGTGTGG-
3’) in murine hindlimbs and wound tissue, and (2) human SIAH1, SIAH2 and β2-
microglobulin (B2M) in cultured HCAECs using primers designed previously (16). Relative 
changes in gene expression were normalized using the ΔΔCT method to murine 36B4 or 
human B2M. 
 
Protein expression 
Whole cell and nuclear protein extracts were subjected to Western blot analysis and probed 
with antibodies for PI3K (p85) (abcam), phosphorylated Akt (Ser473), total Akt (Cell 
Signaling Technology), PHD2, PHD3, HIF-1α (Novus Biologicals), VEGFA (abcam), 
VEGFB, VEGFC, VEGFD (R&D Systems), phosphorylated VEGFR2 (Tyr1175), total 
VEGFR2, phosphorylated eNOS (Ser1177), total eNOS (Cell Signaling Technology) and SR-
BI (Novus Biologicals). Even protein loading was confirmed by α-tubulin (abcam) for whole 
cell lysates or lamin B1 (abcam) for nuclear fractions. Secreted and cytoplasmic VEGFR1 
expression were measured in the media and cytoplasmic fractions by ELISA (R&D Systems). 
 
Matrigel tubulogenesis assay 
Pre-treated HCAECs were seeded at 8x103 cells/well on polymerized growth-factor-reduced 
Matrigel and incubated for 4 hours. Tubules were photographed at 40X magnification under 
light microscopy and total number tubules formed determined using Image J. 
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Statistical analyses 
Data are expressed as mean±SEM. Differences between treatment groups were calculated 
using a one-way ANOVA (Bonferroni’s comparison test post hoc) or Student’s t-test. A two-
way ANOVA (Bonferroni’s comparison test post hoc) was performed when comparing data 
at multiple timepoints. Significance was set at a two-sided P<0.05. 
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Results 
 
rHDL rescues diabetes-impaired angiogenesis in vivo. 
We first studied the effects of rHDL in two models of diabetes-impaired vascular 
complications including: (1) ischemia-mediated neovascularization and (2) wound healing 
and angiogenesis. In the hindlimb ischemia model, femoral artery ligation reduced blood flow 
equally in all mice at Day 0 (Figure 1A). In the non-diabetic mice, rHDL infusions promoted 
blood flow recovery compared with PBS-infused mice, reaching significance at Day 7 
(P<0.05). Diabetes severely impaired blood flow recovery in PBS-infused mice. However, 
this was rescued by rHDL infusions (P<0.01). Consistent with this, rHDL increased capillary 
density in the gastrocnemius muscle of ischemic hindlimbs in both the non-diabetic (P<0.01) 
and diabetic mice (P<0.001) (Figure 1B). The impact of diabetes on wound healing and 
angiogenesis was more striking. In non-diabetic mice, topical rHDL application increased 
wound closure compared to PBS-treated wounds at Day 10 (Figure 1C). As expected, 
diabetic mice exhibited delayed wound closure. Topical rHDL rescued diabetes-related 
impairment in wound closure to the level of non-diabetic controls. Furthermore, in non-
diabetic and diabetic mice, blood perfusion was elevated in rHDL-treated wounds in the 
important early stages of wound recovery (Days 2–6) (Figure 1D). Diabetic mice had reduced 
wound capillary density in PBS-treated wounds (Figure 1E). However, topical rHDL 
enhanced capillary density in diabetic wounds (P<0.05). In both models, we found that 
diabetes suppressed Vegfa expression, which was rescued by rHDL treatment (Supplemental 
Figures 1A-1B). Taken together, we show that rHDL rescues diabetes-impaired angiogenesis. 
These effects were independent of changes in glucose and lipid levels (Supplemental Tables 
1 and 2). Furthermore, rHDL had no effect on markers of glucose metabolism, including the 
glucose transporter Glut1, the metabolic regulator Ppargc1a and three genes involved in 
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metabolic cellular programming: Hif-2α, Phd1 and Pdk4 (Supplemental Figure 2). This 
indicates that rHDL does not mediate its effects on angiogenesis via changes in glucose 
metabolism. Finally, we found there were no differences in Scarb1 (SR-BI) levels between 
diabetic and non-diabetic animals in both studies (Supplemental Figure 3A). However, rHDL 
significantly augmented hindlimb Scarb1 expression in diabetic mice.  
 
rHDL rescues high glucose-impaired HIF-1α stabilization in vitro.  
We then studied the effects of rHDL on key angiogenic pathways in vitro in high glucose 
conditions. Decreased HIF-1α stability, impaired VEGFA production and eNOS inhibition 
are strongly implicated in the pathogenesis of diabetes-impaired angiogenesis (3-6). HIF-1α 
is post-translationally modulated, beginning with the PI3K/Akt signaling pathway, which 
induces the E3 ubiquitin ligases Siah1 and Siah2 (18). Under high glucose conditions, rHDL 
increased PI3K protein expression (Figure 2A, P<0.05) and induced an increase in 
phosphorylated Akt (pAkt) (Figure 2B, P<0.001). rHDL increased SIAH1 and SIAH2 mRNA 
levels, irrespective of glucose conditions (Figures 2C–2D, P<0.001). The Siahs suppress 
prolyl hydroxylases (PHD2 and PHD3) that ubiquitinate and target HIF-1α for degradation. 
Exposure to high glucose increased PHD2 and PHD3 protein levels (Figures 2E–2F). 
However, rHDL suppressed both PHD2 (P<0.01) and PHD3 (P<0.05) levels. Consistent with 
the decreases in PHDs, rHDL rescued high glucose-induced reductions in both total and 
nuclear HIF-1α protein levels (Figures 2G–2H, P<0.05). These results show that rHDL 
rescues high glucose-impaired HIF-1α stabilization in vitro.  
 
rHDL rescues high glucose-impaired VEGFA/VEGFR2 production/activation in vitro.  
While the VEGFA/VEGFR2 signaling axis has been strongly implicated in diabetic vascular 
complications (5), other members of the VEGF ligand-receptor family have also been 
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implicated in diabetes (19-23). We determined the effects of rHDL on the VEGF ligand-
receptor family. rHDL prevented high glucose-induced inhibition of VEGFA and VEGFB 
protein (Figures 3A–3B, P<0.05), but did not change VEGFC or VEGFD levels (Figures 3C–
3D). While high glucose did not impact on VEGFR1 expression, rHDL significantly 
decreased both soluble and cytoplasmic VEGFR1 protein irrespective of glucose conditions 
(Figures 3E–3F). rHDL promoted VEGFR2 phosphorylation (pVEGFR2) (Figure 3G) and 
augmented eNOS phosphorylation in high glucose (Figure 3H). Finally, consistent with 
increases in HIF-1α stabilization, VEGFA/VEGFR2 signaling and eNOS activation, rHDL 
augmented endothelial cell tubule formation (Figure 3I, P<0.05).  
 
Post-translational HIF-1α modulators Siahs mediate rHDL rescue of high glucose-
impaired angiogenesis in vitro.  
To elucidate the importance of Siah1 and Siah2 in rHDL-induced HIF-1α stabilization and 
VEGFA augmentation, a siRNA knockdown approach was used. In the scrambled siRNA 
(siScr) cells, rHDL augmented HIF-1α, VEGFA, pVEGFR2 and tubulogenesis (Figures 4A–
4D) in high glucose. However, knockdown of Siah1 and Siah2 abrogated several steps in the 
angiogenic pathway including rHDL-induced increases in HIF-1, VEGFA, pVEGFR2 and 
tubulogenesis, highlighting an important role for Siahs in mediating the pro-angiogenic 
effects of rHDL in high glucose. 
 
SR-BI mediates rHDL-induced rescue of high glucose-impaired angiogenesis in vitro. 
In HCAECs, high glucose induced a 50% decrease in SR-BI protein (Supplemental Figure 
3B, P<0.05), consistent with previous studies (24-26). Incubation with rHDL prevented high 
glucose-induced SR-BI inhibition (P<0.05). The role of SR-BI in mediating the pro-
angiogenic effects of rHDL in high glucose conditions was next assessed in vitro using a 
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lentiviral SR-BI shRNA (shSR-BI). In the lentiviral control shRNA (shControl) cells, rHDL 
augmented pAkt, however this was abrogated in shSR-BI cells (Figure 5A). rHDL also failed 
to augment HIF-1α expression in shSR-BI cells (Figure 5B). Whilst rHDL increased VEGFA 
protein in shControl cells, this induction was abrogated by shSR-BI (Figure 5C). Finally, 
rHDL-induced tubule formation was attenuated in shSR-BI cells (Figure 5D).  
 
SR-BI mediates rHDL rescue of diabetes-impaired ischemia-induced neovascularization in 
vivo. 
We then investigated the role of SR-BI in mediating the effects of rHDL on ischemia-
mediated neovascularization in vivo using SR-BI-/- mice. In non-diabetic wildtype mice, 
rHDL augmented hindlimb blood perfusion, which was attenuated in non-diabetic SR-BI-/- 
mice (Supplemental Figure 4A). In diabetic wildtype littermates, rHDL infusions promoted 
blood flow recovery, capillary density and augmented mRNA levels of key angiogenic 
mediators including Siah1a, Siah2, Hif-1α and Vegfa (Figures 6A-6F, P<0.05). However, the 
pro-angiogenic ability of rHDL was completely abrogated in SR-BI-/- diabetic mice, 
suggesting that rHDL augments ischemia-induced angiogenesis in diabetes via SR-BI. 
 
SR-BI mediates rHDL rescue of diabetes-impaired wound closure/angiogenesis.  
In non-diabetic wildtype mice, rHDL promoted the rate of wound closure, which did not 
occur in non-diabetic SR-BI-/- mice (Supplemental Figure 4B). In diabetic wildtype 
littermates, rHDL promoted wound closure and wound angiogenesis and induced Siah1a, 
Siah2, Hif-1α, Vegfa and Vegfr2 mRNA levels (Figures 7A-7H, P<0.05). The ability of rHDL 
to promote wound healing and angiogenesis was attenuated in diabetic SR-BI-/- mice. Taken 
together with the in vitro studies reported in Figure 5 and the in vivo hindlimb ischemia 
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studies described in Figure 6, this highlights an important role for SR-BI in the induction of 
angiogenesis by rHDL in diabetes.  
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Discussion 
We report for the first time that rHDL rescues diabetes-impaired angiogenesis by 
enhancement of ischemia-mediated neovascularization and acceleration of wound closure and 
wound angiogenesis. In vitro studies indicate that these effects may, at least in part, be via 
enhanced post-translational HIF-1 modulation and nuclear translocation, increased 
VEGFA/VEGFR2 production and signaling, and augmented eNOS activity. Siah siRNA 
knockdown in vitro confirmed the importance of post-translational HIF-1 modulation in 
mediating the pro-angiogenic effects of rHDL in high glucose. Furthermore, in vitro studies 
using lentiviral shSR-BI knockdown and in vivo studies with SR-BI-/- mice indicate that these 
effects of rHDL are mediated by the receptor SR-BI. In summary, we have demonstrated a 
key role for rHDL in the attenuation of diabetes-related impairment of angiogenesis with 
implications for the therapeutic modulation of diabetic vascular complications. 
 
Collateral vessel network development is an important response to tissue ischemia following 
vascular occlusion (27). Similarly the extent of neovascularization in the early stages 
following wounding is a key determinant of wound closure rate (28). Diabetes is associated 
with poor outcomes following vascular occlusion and impaired coronary collateral 
development (29) and patients with peripheral vascular disease manifest increased peripheral 
limb ulceration and amputation, with cutaneous wounds more prone to amputation (2; 30). 
Consistent with this, our in vivo studies found that diabetes caused impairment of ischemia-
induced neovascularization in hindlimbs and in wound closure/angiogenesis, with a more 
striking impact on wound healing. These are two distinctly different models therefore the 
timing for capturing changes may vary. Compared to the hindlimb ischemia model which is 
primarily driven by ischemia-mediated angiogenesis, wound healing is more complex and not 
solely dependent on angiogenesis but involves other cellular processes including 
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epithelialization and cellular proliferation. Additionally, a chronic inflammatory state as is 
commonly seen in diabetic patients, significantly impairs wound healing and can lead to 
severe unfavorable outcomes such as amputation. HDL also exhibits anti-inflammatory 
effects (31; 32) and may assist in the more robust impact of HDL. Regardless, rHDL 
promoted neovascularization in both angiogenic models, rescuing both ischemia-mediated 
neovascularization and wound healing and angiogenesis, potentially highlighting a new role 
for HDL in attenuating vascular complications associated with diabetes-impaired 
neovascularization.  
 
Our in vitro studies found that high glucose suppressed post-translational HIF-1 modulation 
(via augmentation of PHDs), VEGFA/VEGFR2 production and signaling, and tubulogenesis. 
HIF-1 is the pivotal transcription factor involved in ischemia-mediated neovascularization 
and is governed by a complex orchestration of post-translational regulation. Previous studies 
have reported that hyperglycemia inhibits hypoxia-induced HIF-1α stabilization and suggest 
that mechanisms involving proline hydroxylation are important (33). The current study, 
however, is the first to directly show that high glucose decreases HIF-1 stability via post-
translational effects including an increase in prolyl hydroxylase (PHD2 and PHD3) 
expression and a decrease in both total and nuclear HIF-1 protein. More importantly, rHDL 
rescued HIF-1 stabilization at each step in its post-translational regulation by: 1) activating 
the PI3K/Akt signaling pathway, which 2) triggered an increase in the expression of the E3 
ubiquitin ligases Siahs that 3) suppressed PHD expression and ultimately 4) rescuing 
hyperglycemia-induced reductions in HIF-1. These observations complement a recent study 
that found rHDL increased post-translational HIF-1 stabilization but this study was not 
conducted in high glucose conditions (17). Nuclear localization studies found rHDL 
augmented nuclear HIF-1α protein levels, demonstrating strong evidence of the impact of 
17 
 
rHDL and the Siah/PHD axis on promoting nuclear HIF-1α translocation. Furthermore, 
siRNA knockdown of Siahs confirmed the importance of post-translational HIF-1 
modulation in the effects of rHDL in high glucose, as silencing of the Siahs abrogated key 
steps in the angiogenic pathway in vitro.  
 
As expected, high glucose suppressed VEGFA protein levels in vitro. rHDL treatment 
prevented this decrease, most likely via the stabilization of HIF-1α, the critical transcription 
factor mediating VEGFA expression. Our in vitro analysis of the VEGF ligand-receptor 
family found that rHDL augmented VEGFB but had no effect on VEGFC or VEGFD. Both 
VEGFA and VEGFB bind to VEGFR1, which is also implicated in diabetes-impaired 
neovascularization (19; 34). However, we found that rHDL decreased VEGFR1 expression, 
suggesting that VEGFR1 is not mediating rHDL-induced rescue of angiogenesis in high 
glucose. VEGFR2 is the receptor that regulates the pro-angiogenic effects of VEGFA. 
Following binding of VEGFA to VEGFR2, the receptor dimerizes and causes the activation 
of receptor-kinase activity leading to the phosphorylation of the receptor. Phosphorylated 
VEGFR2 induces the activation of an array of angiogenic signaling pathways (35). We found 
that rHDL increased the phosphorylation (activation) of VEGFR2 in high glucose. This is 
particularly important as hyperglycemia reduces VEGFA sensitivity via suppression of 
VEGFR2 activation (5). Previous studies have found rHDL augments hypoxia-induced 
VEGFR2 total protein levels (14), but this is the first study to show that in high glucose, 
rHDL promotes both VEGFA protein expression and signaling via VEGFR2 
phosphorylation/activation. The present study also found that rHDL promoted eNOS 
phosphorylation in high glucose, which is likely to be due to the increase in 
VEGFA/VEGFR2 and the subsequent increase in Akt phosphorylation (downstream of 
VEGFR2). Elevated eNOS phosphorylation leads to nitric oxide release, promoting 
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angiogenic functions including endothelial cell migration, proliferation and vessel growth 
(36; 37). Consistent with this, other studies have found that rHDL increases eNOS activity in 
vitro and in vivo (38; 39). Finally, using a functional Matrigel assay for endothelial tubule 
formation, we found that rHDL augmented high glucose-impaired tubule formation, 
suggesting that the effects of rHDL on the key angiogenic proteins is translated into critical 
cellular processes involved in angiogenic functions. 
 
It is becoming increasingly recognized that HDL exhibits anti-diabetic effects (9; 40). We 
now show that rHDL rescues diabetes-mediated impairment of hindlimb and wound 
angiogenesis. This is supported by previous work showing that apoA-I/rHDL augment 
ischemia-driven angiogenesis and promote angiogenesis-related functions including 
migration and re-endothelialization (14; 17; 41). However, these studies were not done in the 
clinically relevant setting of hyperglycemia, one of the key contributors to diabetes-impaired 
vascular complications. In the current study, the effects of rHDL were independent of 
changes in glucose and lipid levels. Our in vivo gene analysis of both hindlimb and wound 
tissues found that rHDL had no effect on the expression of the glucose transporter GLUT1 
and the transcriptional coactivator peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), a powerful regulator in metabolism that is involved in HIF-
independent regulation of VEGF and angiogenesis in diabetes (42). Hypoxia tolerance and 
HIF-1α stabilization are central to a hypometabolic state characterized by reduced oxygen 
consumption, such as that seen in diabetes-impaired neovascularization. At a cellular level, 
metabolic cellular reprogramming involves increased efficiency of energy-producing 
pathways, via increased anaerobic glycolysis activity, and decreased energy-consuming 
processes and is mediated via hypoxia-inducible factor-2α (HIF-2α), prolyl hydroxylase 1 
(PHD1) and pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4) (43). rHDL did not 
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have any effect on gene expression of any of these markers. Taken together, this confirms 
that the action of rHDL on diabetes-impaired angiogenesis is not due to glucose stress 
dependent effects but via a number of mechanisms previously found to contribute to diabetes-
impaired neovascularization including: 1) promotion of post-translational HIF-1 
stabilization; 2) VEGFA/VEGFR2 production and signaling; and 3) eNOS activation.  
 
The scavenger receptor SR-BI has been implicated in mediating a number of the endothelial 
protective effects of HDL such as migration, tubulogenesis and re-endothelialization (11; 12; 
17; 44; 45). This is the first study to date that has provided a direct link between SR-BI and 
the pro-angiogenic effects of HDL in diabetes. We found that diabetic animals had slightly 
lower levels of Scarb1 mRNA although this did not reach significance while SR-BI protein 
levels were significantly reduced under high glucose conditions in vitro. Currently, there is 
no consensus on what happens to SR-BI expression in diabetic patients with one study 
reporting elevated SR-BI mRNA levels in diabetic patients (46) while two studies reported no 
differences (47; 48). Data from in vitro studies are more robust. Exposure to high glucose is 
shown to reduce SR-BI levels across several cell types including intestinal Caco-2/15 cells 
(24), hepatic HepG2 cells (25) and human monocyte-derived macrophages (26). More 
importantly, rHDL increased SR-BI expression in vivo and in vitro. Our in vitro and in vivo 
data show that SR-BI is critical in mediating the ability of rHDL to rescue diabetes-impaired 
neovascularization. rHDL was unable to restore high glucose-impaired angiogenesis in shSR-
BI cells in vitro or rescue diabetes-impaired hindlimb and wound angiogenesis/closure in SR-
BI-/- mice in vivo. Furthermore, compared to wildtype littermates of both the hindlimb 
ischemia and wound healing models, we found that the ability of rHDL to augment Siah1a, 
Siah2, Hif-1α, Vegfa and Vegfr2 mRNA levels were attenuated in SR-BI-/- mice. 
Interestingly, SR-BI is the preferred cholesterol acceptor for spherical HDL particles rather 
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than discoidal rHDL (49). However, it would be expected that following incubation in vitro, 
systemic injection in vivo, or topical application to wounds, rHDL would rapidly acquire 
lipid, forming a spherical particle that is able to interact with SR-BI (50). In support of our 
findings, a recent study found that SR-BI acts as a cholesterol sensor triggering intracellular 
signaling and is important for the actions of HDL on endothelial cells (45). SR-BI was also 
important in mediating ischemia-mediated neovascularization and wound 
healing/angiogenesis in non-diabetic mice. The role of SR-BI in angiogenesis is further 
supported by reports that show important signaling pathways including PI3K/Akt are 
downstream of SR-BI and are associated with angiogenesis-related functions such as 
migration and proliferation (12).  
 
Despite the vast number of reports demonstrating the therapeutic benefits of HDL on the 
cardiovascular system, to date there is no translated use of HDL-targeted treatments. There is 
however, increasing evidence for the anti-diabetic effects of HDL which may present an 
alternative translation pathway. We found that rHDL rescues both high glucose-related 
impairment of tubulogenesis in vitro and diabetes-impaired neovascularization in vivo. The 
mechanisms for these effects are via increased post-translational HIF-1 stabilization; 
VEGFA/VEGFR2 production/activation and signaling; and eNOS activation (Figure 8). 
Furthermore, SR-BI is important in mediating rHDL-induced rescue of diabetes-impaired 
angiogenesis. The current study provides a greater understanding into the vascular biological 
effects of HDL in the context of diabetic vascular complications. This may ultimately 
facilitate the translation of HDL, not only for cardiovascular disease but also diseases 
associated with impaired angiogenesis and the vascular complications of diabetes.  
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Figure Legends: 
Figure 1: rHDL rescues diabetes-impaired angiogenesis in vivo. Ischemia-mediated 
Neovascularization: Femoral artery ligation was performed on non-diabetic and diabetic 
C57Bl/6J mice (n=11/group). Mice received i.v. injections of rHDL (200 μg/mouse) or PBS 
(vehicle) on alternate days following ligation until sacrifice. (A) Blood flow perfusion was 
determined using Laser Doppler; images show high (red) to low (blue) blood flow at Day 10. 
Laser Doppler Perfusion Index (LDPI) was determined based on the ratio of ischemic 
(ISC):non-ischemic (NON) hindlimb. White circles, non-diabetic PBS-infused mice; grey 
triangles, non-diabetic rHDL-infused mice; black circles, diabetic PBS-infused mice; and 
blue squares, diabetic rHDL-infused mice. (B) Capillaries were identified using 
immunocytochemistry for CD31+, and quantified as number of vessels per myocyte. 
Photomicrographs represent ischemic gastrocnemius muscle stained for capillaries (CD31+, 
stained red, denoted by arrows) and myocytes (laminin, stained blue). Wound Healing and 
Angiogenesis: Two full thickness wounds were created on non-diabetic and diabetic 
C57Bl/6J mice (n=11/group). Mice received daily topical applications of rHDL (50 
μg/wound) or PBS (vehicle). (C) Wound area was calculated from the average of three daily 
diameter measurements along the x, y and z-axes. Wound closure is expressed as a 
percentage of initial wound area at Day 0. White circles, non-diabetic PBS-treated wound; 
grey triangles, non-diabetic rHDL-treated wound; black circles, diabetic PBS-treated wound; 
and red squares, diabetic rHDL-treated wound. (D) rHDL:PBS wound blood flow perfusion 
ratio was determined using laser Doppler imaging; images represent high (red) to low (blue) 
blood flow at Day 10 in non-diabetic (grey triangles) and diabetic (red squares) mice. (E) 
Capillaries were identified in wound sections using immunohistochemistry for CD31+. 
Photomicrographs represent wounds stained for CD31+ (stained brown, denoted by arrows). 
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Scale bars represent 200 μm. Results are expressed as meanSEM. *P<0.05, **P<0.01, 
***P<0.001 vs. non-diabetic PBS mice; #P<0.05, ##P<0.01, ###P<0.001 vs. diabetic PBS mice. 
 
Figure 2: rHDL rescues high glucose-impaired HIF-1α stabilization in vitro. HCAECs 
were treated with rHDL (20 μM, white bars) or PBS (vehicle, black bars) for 18 h prior to 48 
h glucose exposure (5–25 mM), then utilized for RNA or protein analysis. (A) PI3K, (B) 
phosphorylated Akt (pAkt) relative to total Akt (AktT) protein levels, (C) SIAH1 and (D) 
SIAH2 mRNA levels, normalized to B2M; (E) PHD2, (F) PHD3, (G) total HIF-1α and (H) 
nuclear HIF-1α protein levels. Black line separates noncontiguous lanes from the same gel. 
Results are expressed as meanSEM. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 3: rHDL rescues high glucose-impaired VEGFA/VEGFR2 production/activation 
in vitro. HCAECs were treated with rHDL (20 μM, white bars) or PBS (vehicle, black bars) 
for 18 h prior to 48 h glucose exposure (5–25 mM), then utilized for protein analysis or 
Matrigel tubulogenesis assay. (A) VEGFA, (B) VEGFB, (C) VEGFC, (D) VEGFD, (E) 
secreted VEGFR1, (F) cytoplasmic VEGFR1, (G) phosphorylated VEGFR2 (pVEGFR2) 
relative to total VEGFR2 (VEGFR2T) and (H) phosphorylated eNOS (peNOS) relative to 
total eNOS (eNOST) protein levels. Black line separates noncontiguous lanes from the same 
gel. (I) Representative images of tubule formation photographed at 40X under light 
microscopy. Tubule branches were counted using ImageJ. Results are expressed as 
meanSEM. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 4: Post-translational HIF-1α modulators Siahs mediate rHDL rescue of high 
glucose-impaired angiogenesis in vitro. HCAECs were transfected with scrambled (siScr), 
Siah1 (siSiah1), or Siah2 (siSiah2) siRNA for 6 h then incubated with rHDL (20 μM, white 
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bars) or PBS (vehicle, black bars) for 18 h prior to 48 h in high glucose (25 mM) and utilized 
for protein analysis or Matrigel tubulogenesis assay. (A) HIF-1α, (B) VEGFA, and (C) 
phosphorylated VEGFR2 (pVEGFR2) relative to total VEGFR2 (VEGFR2T) protein levels. 
(D) Representative images of tubule formation photographed at 40X under light microscopy. 
Tubule branches were counted using ImageJ. Results are expressed as meanSEM. *P<0.05, 
**P<0.01 vs. relative PBS controls. 
 
Figure 5: SR-BI mediates rHDL-induced rescue of high glucose-impaired angiogenesis 
in vitro. HCAECs were transduced with lentivirus (1x107 viral particles) expressing shSR-BI-
containing vector (shSR-BI) or the empty vector (shControl). Transduced cells were treated 
with rHDL (20 μM, white bars) or PBS (vehicle, black bars) for 18 h prior to 48 h in high 
glucose (25 mM) then used for protein analysis or Matrigel tubulogenesis assay. (A) 
Phosphorylated Akt (pAkt) relative to total Akt (AktT), (B) HIF-1α and (C) VEGFA protein 
levels. (D) Representative images of tubule formation photographed at 40X under light 
microscopy. Tubule branches were counted using ImageJ. Results are expressed as 
meanSEM. *P<0.05 vs. relative PBS controls. 
 
Figure 6: SR-BI mediates rHDL rescue of diabetes-impaired ischemia-induced 
neovascularization in vivo. Femoral artery ligation was performed on diabetic wildtype 
(WT) and SR-BI-/- mice (n=9-10/group). Mice received i.v. injections of rHDL (200 
μg/mouse) or PBS (vehicle) on alternate days following ligation. (A) Laser Doppler Perfusion 
Index (LDPI) was determined based on the ischemic (ISC):non-ischemic (NON) hindlimb 
ratio. White circles, diabetic WT PBS-infused mice; grey triangles, diabetic WT rHDL-
infused mice; black circles, diabetic SR-BI-/- PBS-infused mice; blue squares, diabetic SR-BI-
/- rHDL-infused mice. (B) Capillaries were identified using immunocytochemistry for CD31+, 
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and quantified as number of vessels per myocyte. Photomicrographs represent ischemic 
gastrocnemius muscle stained for capillaries (CD31+, stained red, denoted by arrows) and 
myocytes (blue). Scale bars represent 200 μm. (C) Siah1a, (D) Siah2, (E) Hif-1α, (F) Vegfa 
and (G) Vegfr2 mRNA levels, expressed as a ratio of ISC:NON, normalized to 36B4. Results 
are expressed as meanSEM. *P<0.05. 
 
Figure 7: SR-BI mediates rHDL rescue of diabetes-impaired wound 
closure/angiogenesis. Two full thickness wounds were created on diabetic wildtype (WT) 
and SR-BI-/- mice (n=7-8/group). Mice received daily topical applications of rHDL (50 
μg/wound) or PBS (vehicle). (A) Wound area was calculated from the average of three daily 
diameter measurements along the x, y and z-axes. Wound closure is expressed as a 
percentage of initial wound area at Day 0: white circles, diabetic WT PBS-treated wound; 
grey triangles, diabetic WT rHDL-treated wound; black circles, diabetic SR-BI-/- PBS-treated 
wound; red squares, diabetic SR-BI-/- rHDL-treated wound. (B) Blood flow perfusion was 
determined using laser Doppler imaging; images represent high (red) to low (blue) blood 
flow at Day 10 in diabetic wildtype (grey triangles) and SR-BI-/- (red squares) mice. (C) 
Capillaries were identified using immunohistochemistry for CD31+ (stained brown, denoted 
by arrows) and expressed relative to wound area. Scale bars represent 200 μm. (D) Siah1a, 
(E) Siah2, (F) Hif-1α, (G) Vegfa and (H) Vegfr2 mRNA levels, normalized to 36B4. Results 
are expressed as meanSEM. *P<0.05. 
 
Figure 8: Proposed mechanism of action of rHDL rescue of diabetes-impaired 
angiogenesis. Under high glucose conditions, rHDL activates the PI3K/Akt pathway, 
inducing the expression of the E3 ubiquitin ligases, Siah1 and Siah2. Increases in Siahs result 
in the inhibition of two members of the prolyl hydroxylase domain protein family, PHD2 and 
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PHD3. Suppression of PHD2/3 prevents HIF-1α from degradation, allowing it to translocate 
to the nucleus and bind to the hypoxia response element (HRE), activating transcription of 
pro-angiogenic mediators including VEGFA. VEGFA is released into the circulation where it 
binds and phosphorylates VEGFR2 further augmenting angiogenesis via the PI3K/Akt 
pathway and eNOS phosphorylation. These effects of rHDL are mediated via SR-BI. ↑ and ↓ 
denotes the effects of rHDL. 
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